Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-192

Also . . .  Additional patients will be added to the third cohort until the current evaluable patients havesafely passed the dose limiting toxicity window.

They've collected extra data from the third cohort.  If results are consistent and persuasive, there could be early interest.

However, Paul Hopper emphasised the 'patience required' aspect of Biotech investment.  P1B results would likely have to be exceptional rather than good if they are to secure a deal.  Also, once Her-vaxx is on board and the vaccine has taken effect, every patient becomes an ongoing advocate for or against long term efficacy and safety.  Numbers are very small so far and any Pharma picking up IMU also picks up the risk of Long Term immune-related side-effects.   Even if P1B results are great, I wouldn't be surprised to see them hold off until LT safety is more evident.

Cheers